MediciNova Announces Completion of Patient Enrollment Evaluating MN-166 (ibudilast) in the Prevention of Chemotherapy-induced Peripheral Neuropathy

Core Insights - MediciNova, Inc. has successfully completed patient enrollment in the Phase 2 clinical trial, OXTOX study, evaluating MN-166 (ibudilast) for preventing chemotherapy-induced peripheral neuropathy in metastatic colorectal cancer patients [1][2] Group 1: Clinical Trial Details - The OXTOX study is a randomized, placebo-controlled trial with 100 patients enrolled across 11 clinical sites in Australia [1] - Participants will continue chemotherapy along with either MN-166 or placebo until disease progression or unacceptable side effects, with the study concluding when the final patient reaches six months post-chemotherapy [2] Group 2: About MN-166 (ibudilast) - MN-166 (ibudilast) is a small molecule compound that inhibits phosphodiesterase type-4 (PDE4) and inflammatory cytokines, currently in late-stage clinical development for various neurodegenerative diseases, including ALS and progressive MS [3] - The compound has Orphan Drug Designation and Fast Track Status from the US FDA for ALS, and Orphan Drug Designation from the EMA [3] Group 3: About MediciNova - MediciNova is a clinical-stage biopharmaceutical company focused on developing novel small molecule therapies for inflammatory, fibrotic, and neurodegenerative diseases [4] - The company has a strong pipeline, with MN-166 in Phase 3 for ALS and DCM, and MN-001 (tipelukast) in Phase 2 for treating hypertriglyceridemia in type 2 diabetic patients [4]